Provista Diagnostics

Provista Diagnostics is a private molecular diagnostics company focused on developing and commercializing a new generation of proprietary blood proteomic diagnostics, prognostics, and monitoring tests to address unmet needs in women's cancers such as breast and gynecological cancers. Provista Diagnostics' state-of-the-art, high-complexity clinical laboratory is accredited by the College of American Pathologists (CAP) and the Clinical Laboratory Improvement Amendments (CLIA). The company concentrates on oncology-related diagnostics, where the clinical demand for such testing products is very high and remains unmet. Recent development and commercialization efforts have been centered on women's cancers, including breast and ovarian cancer.